Biotech drugs such as genetically engineered hormones and monoclonal antibodies make up a sizeable and growing proportion of the pharmaceutical market. Biologics represented 7% of the pharmaceutical market in 2002, and by 2006 they are expected to make up 12%. Seven hundred new biologics are currently being tested, with up to 200 entering late-stage trials. This year, as many as 40 new biologics could make it to the market, according to Kalorama Information, a life science market research firm in New York.1
Reducing expenses has become one of healthcare's major woes. As biologics continue to capture market share, they will also be scrutinized for ways to cut cost. Experts say that biomanufacturers have come under increasing pressure to address the problem.
Making biotech drugs is an expensive business. Of the estimated 170 biomanufacturers worldwide, nearly one-half are located in the United States.2 Mark Bamforth, senior vice president for corporate operations ...
